ArticleDrug delivery and translational research2013
Self-assembling peptide scaffolds as innovative platforms for drug and cell delivery systems in cardiac regeneration.
Article in Drug delivery and translational research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 6 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Today, the use of biomaterials in many biomedical platforms is becoming increasingly popular due to their high diversity, infinite mimicking capacity, and emerging functions. Applications currently cover diverse areas in biomedicine including systems for cell isolation, expansion and maintenance, platforms for drug and cell delivery, scaffolds for tissue engineering, tissue regeneration and repair, cancer therapy, etc. Biomaterials in general can be: (1) natural in origin such as many proteins from the extracellular matrix, natural polysaccharides or scaffolds presented in a blood clot or (2) synthetic, including polymers, ceramics, or peptides. In this review, we focus on the use of self-assembling peptide scaffolds as an innovative and reliable strategy to obtain platforms for cell and drug delivery to injured or diseased tissues and organs. This type of material is molecular by design and it develops spontaneously into nanofiber scaffolds with multiple uses. In particular, examples are given for applications in the area of cardiac repair and regeneration.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.